Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

Bianca Weinstock-Guttman, Dana Horakova, Robert Zivadinov, Miriam Tamaño-Blanco, Darlene Badgett, Michaela Tyblova, Manuela Vaneckova, Zdenek Seidl, Jan Krasensky, Niels Bergsland, Deepa P. Ramasamy, Jesper Hagemeier, Eva Havrdova, Murali Ramanathan

Research output: Contribution to journalArticle

Abstract

Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24. months after start of interferon-beta treatment. Results: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1 ± SD 8.1. years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C ( p= 0.009) and TC ( p= 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse ( p= 0.006) and the greater number of relapses ( p= 0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new T2 lesions ( p= 0.002) and with increased brain atrophy (p <0.001) in patients with high LDL-C. Conclusions: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C.

Original languageEnglish
Pages (from-to)121-127
Number of pages7
JournalJournal of Neuroimmunology
Volume263
Issue number1-2
DOIs
Publication statusPublished - Oct 15 2013

Fingerprint

Epstein-Barr Virus Nuclear Antigens
Herpesviridae
Disease Progression
Cholesterol
Human Herpesvirus 4
Antibodies
LDL Cholesterol
HDL Cholesterol
Serum
Recurrence
Interferon-beta
Cytomegalovirus
Atrophy
Anti-Idiotypic Antibodies
Immunoglobulin G
Lipids
Brain
Therapeutics
Epstein-Barr viral capsid antigen

Keywords

  • Cholesterol
  • Clinically isolated syndromes
  • Environmental factor interactions
  • Epstein-Barr virus
  • Lipid
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Weinstock-Guttman, B., Horakova, D., Zivadinov, R., Tamaño-Blanco, M., Badgett, D., Tyblova, M., ... Ramanathan, M. (2013). Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 263(1-2), 121-127. https://doi.org/10.1016/j.jneuroim.2013.07.010

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. / Weinstock-Guttman, Bianca; Horakova, Dana; Zivadinov, Robert; Tamaño-Blanco, Miriam; Badgett, Darlene; Tyblova, Michaela; Vaneckova, Manuela; Seidl, Zdenek; Krasensky, Jan; Bergsland, Niels; Ramasamy, Deepa P.; Hagemeier, Jesper; Havrdova, Eva; Ramanathan, Murali.

In: Journal of Neuroimmunology, Vol. 263, No. 1-2, 15.10.2013, p. 121-127.

Research output: Contribution to journalArticle

Weinstock-Guttman, B, Horakova, D, Zivadinov, R, Tamaño-Blanco, M, Badgett, D, Tyblova, M, Vaneckova, M, Seidl, Z, Krasensky, J, Bergsland, N, Ramasamy, DP, Hagemeier, J, Havrdova, E & Ramanathan, M 2013, 'Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes', Journal of Neuroimmunology, vol. 263, no. 1-2, pp. 121-127. https://doi.org/10.1016/j.jneuroim.2013.07.010
Weinstock-Guttman, Bianca ; Horakova, Dana ; Zivadinov, Robert ; Tamaño-Blanco, Miriam ; Badgett, Darlene ; Tyblova, Michaela ; Vaneckova, Manuela ; Seidl, Zdenek ; Krasensky, Jan ; Bergsland, Niels ; Ramasamy, Deepa P. ; Hagemeier, Jesper ; Havrdova, Eva ; Ramanathan, Murali. / Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. In: Journal of Neuroimmunology. 2013 ; Vol. 263, No. 1-2. pp. 121-127.
@article{eee1c656b28644c4aac970194dc3a058,
title = "Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes",
abstract = "Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24. months after start of interferon-beta treatment. Results: The study included 118 CIS patients (77 females, 41 males, 65.3{\%} female; mean age: 28.1 ± SD 8.1. years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C ( p= 0.009) and TC ( p= 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse ( p= 0.006) and the greater number of relapses ( p= 0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new T2 lesions ( p= 0.002) and with increased brain atrophy (p <0.001) in patients with high LDL-C. Conclusions: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C.",
keywords = "Cholesterol, Clinically isolated syndromes, Environmental factor interactions, Epstein-Barr virus, Lipid, Multiple sclerosis",
author = "Bianca Weinstock-Guttman and Dana Horakova and Robert Zivadinov and Miriam Tama{\~n}o-Blanco and Darlene Badgett and Michaela Tyblova and Manuela Vaneckova and Zdenek Seidl and Jan Krasensky and Niels Bergsland and Ramasamy, {Deepa P.} and Jesper Hagemeier and Eva Havrdova and Murali Ramanathan",
year = "2013",
month = "10",
day = "15",
doi = "10.1016/j.jneuroim.2013.07.010",
language = "English",
volume = "263",
pages = "121--127",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

AU - Weinstock-Guttman, Bianca

AU - Horakova, Dana

AU - Zivadinov, Robert

AU - Tamaño-Blanco, Miriam

AU - Badgett, Darlene

AU - Tyblova, Michaela

AU - Vaneckova, Manuela

AU - Seidl, Zdenek

AU - Krasensky, Jan

AU - Bergsland, Niels

AU - Ramasamy, Deepa P.

AU - Hagemeier, Jesper

AU - Havrdova, Eva

AU - Ramanathan, Murali

PY - 2013/10/15

Y1 - 2013/10/15

N2 - Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24. months after start of interferon-beta treatment. Results: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1 ± SD 8.1. years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C ( p= 0.009) and TC ( p= 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse ( p= 0.006) and the greater number of relapses ( p= 0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new T2 lesions ( p= 0.002) and with increased brain atrophy (p <0.001) in patients with high LDL-C. Conclusions: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C.

AB - Objectives: To investigate whether anti-herpesvirus antibodies are associated with serum cholesterol profiles in clinically isolated syndromes (CIS). Methods: Pre-treatment serum samples from 118 high-risk CIS patients were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) viral capsid antigen (VCA) and EBV nuclear antigen-1 (EBNA-1). A lipid profile consisting of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) was obtained. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24. months after start of interferon-beta treatment. Results: The study included 118 CIS patients (77 females, 41 males, 65.3% female; mean age: 28.1 ± SD 8.1. years). Anti-EBV EBNA-1 antibody levels were associated with LDL-C ( p= 0.009) and TC ( p= 0.008) levels. Anti-CMV positivity status was associated with reduced time to relapse ( p= 0.006) and the greater number of relapses ( p= 0.009) in patients with high HDL-C. Anti-EBV VCA antibody levels were associated with greater number of new T2 lesions ( p= 0.002) and with increased brain atrophy (p <0.001) in patients with high LDL-C. Conclusions: Our results indicate that higher levels of anti-EBV EBNA-1 antibodies are associated with higher LDL-C and TC levels. Anti-CMV positive individuals have greater disease progression in the presence of higher HDL-C levels. Individuals with higher levels of anti-EBV VCA antibodies have greater progression on MRI measures in the presence of higher LDL-C.

KW - Cholesterol

KW - Clinically isolated syndromes

KW - Environmental factor interactions

KW - Epstein-Barr virus

KW - Lipid

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84884812196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884812196&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2013.07.010

DO - 10.1016/j.jneuroim.2013.07.010

M3 - Article

C2 - 23916695

AN - SCOPUS:84884812196

VL - 263

SP - 121

EP - 127

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -